Hormone therapy myths and facts after 40

Menopause hormone therapy is often discussed as though it were a single treatment with one universal answer. At the Healthy Lifestyle Expo on Queensland’s Sunshine Coast, conversations with doctors, scientists, natural health experts and exhibitors can place that debate in a useful context: who may benefit, what the evidence supports, and why individual assessment matters.

Myths about hormone therapy after 40 tend to swing between two extremes: the idea that it is a risky shortcut to youth, or the idea that every symptom of ageing should be treated with hormones. Neither reflects modern clinical evidence. A sound decision depends on the symptom, its effect on daily life, medical history and the time since menopause.

Hormones change, but ageing is not one simple process

Perimenopause often begins in the mid-40s, although timing varies. Ovarian hormone production becomes less predictable, while the ovaries do not simply switch off at one moment. Hot flushes, night sweats, altered periods, disrupted sleep and changes in vaginal tissue can appear during this transition. Menopause is generally diagnosed after 12 months without a period, and symptoms can continue for years.

Not every change in sleep, mood, weight or energy is caused by menopause. Stress, thyroid conditions, iron deficiency, medicines and reduced physical activity can overlap. After 40, the same symptom may have several causes, so replacing a hormone without understanding the pattern can miss something important.

Menopause hormone therapy has benefits and limits

Menopause hormone therapy, usually shortened to MHT, has the strongest evidence for treating moderate to severe vasomotor symptoms, meaning hot flushes and night sweats. It can also treat genitourinary symptoms such as vaginal dryness, soreness and irritation, often with local rather than whole-body therapy. Sleep may improve when night sweats were the main driver, but insomnia with another cause needs its own assessment. MHT regimens are not reliable contraceptives.

MHT is not a general anti-ageing treatment. It has not been shown to prevent heart attacks, strokes, dementia or diabetes in people without those conditions, and it should not be started solely for that purpose. Although oestrogen helps protect bone, it is not usually the first choice for someone with osteoporosis when other treatments are suitable.

Benefits and risks depend on the formulation, route, dose, duration, age and baseline risk. Oral systemic oestrogen carries a greater risk of venous thromboembolism than transdermal oestrogen, while some oestrogen-plus-progestogen regimens can increase breast cancer risk with longer use. A person with a uterus generally needs a progestogen to protect the uterine lining when using systemic oestrogen; this is not an optional extra.

Common claims compared with current evidence

Clear questions deserve clear answers without marketing spin. The following distinctions help separate established benefits from claims that are unsupported or oversimplified.

Claim What the evidence shows Practical response
Turning 40 means starting HRT Age alone is not an indication. MHT is considered for appropriate symptoms, with benefits and risks assessed individually. Start with symptoms and medical history, not a birthday.
It is too late after 50 The benefit-risk balance varies, and timing matters. Age alone does not create an automatic cut-off for suitable treatment. Consider your age, time since menopause and risk factors together.
Bioidentical or natural means safer Labels do not guarantee a safer product. Approved products undergo regulation; compounded hormones can have inconsistent doses. Check the exact product and avoid unverified online purchases.
HRT protects the heart and brain Evidence does not support starting systemic MHT to prevent cardiovascular disease or dementia. Address blood pressure, cholesterol, activity and smoking directly.
HRT reliably causes weight loss Menopause and ageing affect weight through several factors. MHT is not an established weight-loss therapy. Use nutrition, strength and sleep support alongside symptom treatment.
Once symptoms settle, review is unnecessary Follow-up can check benefit, side effects and changes in risk. Blood tests are tailored rather than automatically repeated. Agree on a review schedule and when to seek help again.

These distinctions do not decide the issue for an individual. Symptom severity, medical history and time since menopause can change the balance of benefits and risks. A clinician also needs to distinguish MHT from treatments for insomnia, weight loss, low libido or thyroid disease.

What Australian pathways and safeguards involve

In Australia, conversations may use HRT, MHT and hormone replacement therapy almost interchangeably. MHT is the preferred clinical term because “replacement” can suggest hormones are simply restoring a younger body. Most people begin with a GP, who can prescribe, review risk factors and refer to a menopause or endocrine specialist when the history is complex. Pharmacists can also help with product information, repeats and practical questions.

Medicare rebates cover the consultation, but usually not the hormone medicine itself. Some menopause treatments receive Pharmaceutical Benefits Scheme subsidy, while access varies by product and eligibility. Current listings should be checked rather than assumed, particularly during supply disruptions. Prescribed medicine should never be rationed without discussing it with a prescriber or pharmacist.

The TGA regulates approved medicines and their advertising. A product described as “natural”, “bioidentical” or “compounded” is not automatically safer, and compounded preparations may not provide a consistent dose. Checking the exact product, active ingredient and route matters more than the marketing label, especially when a clinician has recommended a particular formulation.

Before a screening conversation at the Healthy Lifestyle Expo, visitors can prepare for screening by bringing a medication and supplement list, relevant results and a short symptom history. An expo discussion can clarify questions and options, but it does not replace a medical diagnosis or a review of unexplained bleeding, chest symptoms or other warning signs.

A focused checklist for expo visitors

The Healthy Lifestyle Expo brings conventional medicine and holistic practice into the same conversation, which makes preparation useful. The guide on what to bring can help visitors organise questions and distinguish general information from a personalised recommendation.

A good conversation should leave you better able to describe your priorities and seek an individual plan through a GP or menopause clinician. It should not require you to commit to a product at the event.

Turning information into a personal plan

A clinician can help set goals, select an effective dose and duration, and arrange follow-up based on symptom relief and risk. Complex histories, recurrent migraines, a personal or family history of breast cancer, previous blood clots or persistent abnormal bleeding warrant careful assessment, often through a specialist. Online hormone powders, pellets and unlabelled compounded products are not a substitute for that review.

The practical takeaway is to match the treatment to the symptom: whether hot flushes, vaginal symptoms, sleep disruption or general fatigue is the main concern; combine that with your medical history and preferences; and review both benefit and risk with a qualified clinician. This is more reliable than treating a single hormone result, an online comment or a product label as a verdict on ageing.